In (peripheral) macrophages, TRIM66 is involved in upregulating the expression of endogenous interferon beta (IFNB1) [67], which is interesting as recombinant, exogenous IFNB1 is one of the earliest and still used disease-modifying treatments for MS [68]. This evidence concerns the gene TRIM66 and myeloid sarcoma.